LEVOXYL Drug Patent Profile
✉ Email this page to a colleague
When do Levoxyl patents expire, and when can generic versions of Levoxyl launch?
Levoxyl is a drug marketed by King Pharms and is included in one NDA.
The generic ingredient in LEVOXYL is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Levoxyl
A generic version of LEVOXYL was approved as levothyroxine sodium by MYLAN on June 5th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LEVOXYL?
- What are the global sales for LEVOXYL?
- What is Average Wholesale Price for LEVOXYL?
Summary for LEVOXYL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 114 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,345 |
| Drug Prices: | Drug price information for LEVOXYL |
| Drug Sales Revenues: | Drug sales revenues for LEVOXYL |
| What excipients (inactive ingredients) are in LEVOXYL? | LEVOXYL excipients list |
| DailyMed Link: | LEVOXYL at DailyMed |
Recent Clinical Trials for LEVOXYL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | N/A |
| Children's Hospital of Philadelphia | N/A |
Pharmacology for LEVOXYL
| Drug Class | l-Thyroxine |
US Patents and Regulatory Information for LEVOXYL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-001 | May 25, 2001 | AB1,AB3 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-007 | May 25, 2001 | AB1,AB3 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-004 | May 25, 2001 | AB1,AB3 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-012 | May 25, 2001 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-008 | May 25, 2001 | AB1,AB3 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LEVOXYL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-006 | May 25, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-005 | May 25, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-012 | May 25, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-004 | May 25, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-001 | May 25, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LEVOXYL
See the table below for patents covering LEVOXYL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 03061557 | ⤷ Sign Up | |
| European Patent Office | 1474103 | ⤷ Sign Up | |
| European Patent Office | 1365745 | ⤷ Sign Up | |
| Japan | 2005517720 | ⤷ Sign Up | |
| South Korea | 20040100835 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
